Mode
Text Size
Log in / Sign up
N/A N=10 Randomized Treatment

Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Radiation for Breast Cancer

Breast Cancer

Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Aug 2021
Primary outcome: Primary: Residual Motion During Deep Inspiratory Breath-Hold (DIBH) — 0.27; 0.27 mm

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Active Breathing Coordinator (ABC) (Device); VisionRT (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
University of Texas Southwestern Medical Center
Primary completion
Sep 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Residual Motion During Deep Inspiratory Breath-Hold (DIBH)
0.27; 0.27
SECONDARY
Time of Simulation
40.0; 29.8
SECONDARY
Time of Treatment in Minutes
9.9; 9.7
SECONDARY
Reproducibility as Measure of Absolute Change of Breathing Chest Wall Excursion
0.51; 0.54
SECONDARY
Radiation Dose to Heart
1.6; 1.6
SECONDARY
Radiation Dose to Lung
6.3; 6.3

Summary

Female patients treated with radiation for left-sided breast malignancy will undergo alternate fractions of Active Breathing Coordinator (ABC)-assisted and VisionRT-assisted Deep Inspiration Breath-Hold (DIBH).

Eligibility Criteria

Inclusion Criteria

  • Women with diagnosis of breast malignancy
  • Women whom requires left chest wall post-mastectomy radiation with or without bolus
  • Age ≥ 18 years.
  • Performance status ECOG </=3
  • Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately Ability to understand and the willingness to sign a written informed consent.
  • Patient must be able to maintain a 30 second breath hold.
  • Conventional chest wall radiation delivery dose of 50.4 Gy/ 28 fractions with or without a boost (boost will not be evaluated for endpoints)

Exclusion Criteria

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02694029). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search